spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Zyprexa 

 HSMN NewsFeed - 6 Jul 2021
Delix Therapeutics Expands Executive Leadership Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Aug 2018
Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 24 Apr 2018
Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Aug 2013
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Feb 2013
Repros Therapeutics Corporate Update
Biopharmaceuticals FDA Personnel
 HSMN NewsFeed - 24 Jul 2012
Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Nov 2010
Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2010
Euthymics Bioscience, Inc. Appoints Industry Veterans Dr. Pierre Trân, Joan Manthis and William Pappafotopoulos to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2010
Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Jul 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2008
Eli Lilly and Company Resolves Investigation Involving Numerous States
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2008
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2008
Lilly Announces Changes in Key Leadership Roles
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Feb 2008
ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Feb 2008
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2007
Statement of Eli Lilly and Company on Dr. David Egilman Settlement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 23 Aug 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jun 2007
Eli Lilly and Company Comments on Recent Court Rulings Regarding Zyprexa(R) Patents
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Feb 2007
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 26 Dec 2006
U.S. Appeals Court Upholds Lilly's 2011 Zyprexa Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 Dec 2006
Eli Lilly and Company Statement Regarding Today's New York Times Article - December 21, 2006
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Barr Receives Tentative Approval for a Generic Version of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg and 20mg
Biopharmaceuticals FDA Generics
 HSMN NewsFeed - 17 Oct 2006
Lilly Announces Acquisition of ICOS Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Oct 2006
OREXIGEN(TM) Therapeutics Expands Senior Management Team as Lead Products Advance Through Late-Stage Clinical Trials
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2006
Government Approves Lilly's Medicare Part D Patient Assistance Program
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
Zyprexa
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.